[
  {
    "ts": null,
    "headline": "Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?",
    "summary": "Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.",
    "url": "https://finnhub.io/api/news?id=2440f4d3266828617b44e82c39c5758131522f9145147a19bb291146cb198034",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765479820,
      "headline": "Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?",
      "id": 137760498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.",
      "url": "https://finnhub.io/api/news?id=2440f4d3266828617b44e82c39c5758131522f9145147a19bb291146cb198034"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Q3 2024 Earnings Call Transcript",
    "summary": "Stéphane Bancel: Thank you, Lavina.  In the third quarter of 2024 compared to the first quarter of 2023, we reduced operating expenses by $500 million across cost of sales, RD and SG&A. This figure excludes $1.4 billion of resizing charge in the first quarter of 2023.  Stéphane Bancel: This year, the COVID market benefited from U.S. regulatory approval that was 19 days earlier than in 2023.",
    "url": "https://finnhub.io/api/news?id=edbad7f877bc6c830b351fcca3931bcbd776e00b2e6d27743c2f277d46237b7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765475870,
      "headline": "Moderna (MRNA) Q3 2024 Earnings Call Transcript",
      "id": 137760209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Stéphane Bancel: Thank you, Lavina.  In the third quarter of 2024 compared to the first quarter of 2023, we reduced operating expenses by $500 million across cost of sales, RD and SG&A. This figure excludes $1.4 billion of resizing charge in the first quarter of 2023.  Stéphane Bancel: This year, the COVID market benefited from U.S. regulatory approval that was 19 days earlier than in 2023.",
      "url": "https://finnhub.io/api/news?id=edbad7f877bc6c830b351fcca3931bcbd776e00b2e6d27743c2f277d46237b7e"
    }
  },
  {
    "ts": null,
    "headline": "Moderna signs deal worth up to $503m with Nanexa",
    "summary": "Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent dosing.",
    "url": "https://finnhub.io/api/news?id=b26b76228efe73407f35910c81dea651127841c9e3cb8e43ad2aa67d1c9ff3c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765475431,
      "headline": "Moderna signs deal worth up to $503m with Nanexa",
      "id": 137760210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent dosing.",
      "url": "https://finnhub.io/api/news?id=b26b76228efe73407f35910c81dea651127841c9e3cb8e43ad2aa67d1c9ff3c0"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Q3 2025 Earnings Call Transcript",
    "summary": "Stéphane Bancel: In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, mRESVIA.  Stéphane Bancel: During the quarter, we made good progress across our 3 strategic priorities.  For Spikevax, our original COVID vaccine, we received approval in 40 countries for the seasonal 2025-2026 strain update.",
    "url": "https://finnhub.io/api/news?id=d5c0b64e56b0d6dc9177a5c2997e0fba25e89c4b45208d5ee253b0da687bdf90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765475090,
      "headline": "Moderna (MRNA) Q3 2025 Earnings Call Transcript",
      "id": 137760211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Stéphane Bancel: In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, mRESVIA.  Stéphane Bancel: During the quarter, we made good progress across our 3 strategic priorities.  For Spikevax, our original COVID vaccine, we received approval in 40 countries for the seasonal 2025-2026 strain update.",
      "url": "https://finnhub.io/api/news?id=d5c0b64e56b0d6dc9177a5c2997e0fba25e89c4b45208d5ee253b0da687bdf90"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update",
    "summary": "Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that it had secured a five-year loan of $1.5 billion from Ares Management Corp (NYSE:ARES). The company made this announcement as it prepared to unveil strategy updates to analysts later that day. Moderna plans to […]",
    "url": "https://finnhub.io/api/news?id=5ed197a340cb6b5733e8b1c32af372bc46792312d8bb6c8a38fbd215bcf3ce83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765457071,
      "headline": "Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update",
      "id": 137757154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that it had secured a five-year loan of $1.5 billion from Ares Management Corp (NYSE:ARES). The company made this announcement as it prepared to unveil strategy updates to analysts later that day. Moderna plans to […]",
      "url": "https://finnhub.io/api/news?id=5ed197a340cb6b5733e8b1c32af372bc46792312d8bb6c8a38fbd215bcf3ce83"
    }
  }
]